Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Eradication rates
Systematic review	2159 people 11 RCTs in this analysis	Eradication rates 963/1117 (86%) with esomeprazole-based triple regimens 843/1029 (82%) with omeprazole- or pantoprazole-based triple regimens	OR 1.38 95% CI 1.09 to 1.75	Small effect size	esomeprazole-based regimens
Systematic review	833 people 2 RCTs in this analysis	Eradication rates 364/415 (88%) with omeprazole-based triple regimen 372/418 (89%) with esomeprazole-based triple regimen	OR 0.89 95% CI 0.58 to 1.35		Not significant
Systematic review	1596 people 6 RCTs in this analysis	Eradication rates 689/811 (85%) with esomeprazole-based triple regimens 649/785 (83%) with omeprazole- or pantoprazole-based triple regimens	OR 1.17 95% CI 0.89 to 1.54		Not significant
Systematic review	1337 people 7 RCTs in this analysis	Eradication rates 444/534 (83%) with pantoprazole-based triple regimens 486/603 (81%) with triple regimens based on other proton pump inhibitors	OR 1.00 95% CI 0.61 to 1.64		Not significant
Systematic review	2226 people 12 RCTs in this analysis	Eradication rates 852/1076 (79%) with rabeprazole-based triple regimens 886/1150 (77%) with triple regimens based on other proton pump inhibitors	OR 1.21 95% CI 0.97 to 1.52 The analysis includes one RCT comparing rabeprazole-based triple regimen versus a proton pump inhibitor-based dual regimen		Not significant
Systematic review	550 people 3 RCTs in this analysis	Eradication rates 264/326 (81%) with lansoprazole-based triple regimen 192/224 (86%) with rabeprazole-based triple regimen	OR 0.77 95% CI 0.48 to 1.22		Not significant
Systematic review	1085 people 6 RCTs in this analysis	Eradication rates 399/534 (75%) with omeprazole-based triple regimen 419/551 (76%) with lansoprazole-based triple regimen	OR 0.91 95% CI 0.69 to 1.21		Not significant
Systematic review	825 people 4 RCTs in this analysis	Eradication rates 328/421 (78%) with omeprazole-based triple regimen 328/404 (81%) with rabeprazole-based triple regimen	OR 0.81 95% CI 0.58 to 1.15		Not significant
RCT	101 people with H pylori infection and active duodenal ulcers	Eradication rates 81% with rabeprazole-based triple regimen for 7 days (including clarithromycin plus amoxicillin) 70% with omeprazole-based triple regimen for 7 days (including clarithromycin plus amoxicillin)	P >0.05		Not significant
RCT	345 people with H pylori infection and current or previously active peptic ulcers	Eradication rates 77% with rabeprazole-based triple regimen for 7 days 75% with omeprazole-based triple regimen for 7 days	difference: +2% 95% CI −7% to +10%		Not significant
RCT	90 people with H pylori infection and non-ulcer dyspepsia	Eradication rates 6 weeks 28/45 (62%) with pantoprazole-based triple regimen for 14 days (including clarithromycin plus amoxicillin) 27/45 (60%) with lansoprazole-based triple regimen for 14 days (including clarithromycin plus amoxicillin)	P >0.05		Not significant